Pen Needles

Pen Needles


Global Pen Needles Market to Reach US$4.8 Billion by 2030

The global market for Pen Needles estimated at US$2.6 Billion in the year 2023, is expected to reach US$4.8 Billion by 2030, growing at a CAGR of 9.2% over the analysis period 2023-2030. Standard Pen Needles, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$2.6 Billion by the end of the analysis period. Growth in the Safety Pen Needles segment is estimated at 11.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$836.5 Million While China is Forecast to Grow at 10.3% CAGR

The Pen Needles market in the U.S. is estimated at US$836.5 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$381.7 Million by the year 2030 trailing a CAGR of 10.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.0% and 8.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.4% CAGR.

Global Pen Needles Market - Key Trends & Drivers Summarized

Pen needles are essential components used with injection pens to deliver medications such as insulin, growth hormones, and other therapeutic agents. These needles are designed to be attached to the pen device, providing a convenient and precise method for administering subcutaneous injections. Pen needles come in various lengths and gauges, allowing patients and healthcare providers to select the most appropriate needle for different injection sites and patient needs. The design of pen needles focuses on minimizing pain and discomfort during injections, with features such as ultra-thin walls, fine tips, and lubricated coatings. This makes pen needles particularly suitable for patients requiring frequent injections, such as those with diabetes who need regular insulin administration.

Technological advancements have led to significant improvements in the design and functionality of pen needles. Modern pen needles incorporate advanced manufacturing techniques that enhance sharpness and reduce penetration force, resulting in less painful injections. Innovations such as safety pen needles, which feature built-in shields to prevent needlestick injuries, have improved safety for both patients and healthcare providers. Additionally, the development of shorter and finer needles has made injections less intimidating and more comfortable, encouraging better adherence to treatment regimens. The use of high-quality materials ensures the durability and reliability of pen needles, providing consistent performance with each use. These advancements have expanded the adoption of pen needles across various therapeutic areas, making them a preferred choice for medication delivery.

The growth in the pen needles market is driven by several factors, including the rising prevalence of diabetes, increasing adoption of self-administration of medications, and advancements in needle technology. The global increase in diabetes cases has significantly boosted the demand for insulin delivery devices, including pen needles. The trend towards self-administration of medications, driven by patient convenience and the need for regular therapy, has further fueled market growth. Technological advancements, such as the development of safety and ultra-fine pen needles, have enhanced the safety and comfort of injections, encouraging broader adoption among patients. Additionally, the increasing availability of pen needles in various lengths and gauges has provided more options for personalized treatment, catering to diverse patient needs. Government initiatives and healthcare policies promoting diabetes management and the use of advanced drug delivery systems are also contributing to the growth of the pen needles market.

Select Competitors (Total 63 Featured) -
  • Advin Health Care
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Cipla Ltd.
  • ARKRAY, Inc.
  • Gerresheimer AG
  • A. Menarini Diagnostics Srl
  • Exelint International Co.
  • Hindustan Syringes & Medical Devices Ltd.
  • Allison Medical, Inc.
  • HTL-Strefa SA
  • GlucoRx Ltd.
  • Cambridge Sensors Ltd.
  • Igaku Needles Private Limited
  • AdvaCare Pharma
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Pen Needles - Global Key Competitors Percentage Market Share in 2024 (E)
Pen Needles Competitor Market Share Scenario Worldwide (in %): 2022E
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
Needles: A Prelude
Types of Needles
An Insight into Pen Needles
Pen Needles for Insulin Injection
Global Market Analysis and Prospects
Global Pen Needles Market Set for a Rapid Growth
Standard Pen Needles Dominate, Safety Pen Needles to Witness Fastest Growth
Emerging Markets: Focal Point for Future Growth
Competitive Landscape
Top Pen Needle Products
Recent Market Activity
WORLD BRANDS
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rise in Diabetic Population Continues to Drives Demand for Pen Needles
World Diabetes and Population Statistics (2019, 2030 & 2045)
Global Prevalence of Diabetes: Number of Adults Diagnosed with Diabetes (in Million) by Gender for 2019, 2030 and 2045
World Diabetes Prevalence (2000-2045P)
Top 10 Countries with Highest Number of Adults Diagnosed with Diabetes (in Million) for 2019 and 2045
Global Diabetes Mellitus Population Breakdown by Geographic Region: 2019, 2030 and 2045?
Diabetes Emerges as One of the Leading Causes of Mortality
Diabetes-Related Deaths as % of Total Deaths in Below 60 Years Population by Region: 2023
Growing Prevalence of Chronic Diseases Drive the Demand for Pen Needles
Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
Global Number of New Cancer Cases and Cancer-related Deaths by Cancer Site for 2018
Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
High Risk of Diabetes in the Fast Expanding Aging Population Benefit Market Expansion
Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
Pen Needles Gain Traction as Insulin Pens Rise in Popularity for Administering Insulin
Smart Insulin Pens: A Growing Area of Interest
Increasing Role of Self-Injection Devices in Diabetes Management
Needle-Free Alternatives: A Growing Threat
Innovative Technologies Revolutionize Pen Needles Market
Advancements in Insulin Delivery Methods Drive the Demand for Pen Needles
Advancements in Pen Needle Technology
Droplet Micron Insulin Needle Represents Innovation in the Diabetes Supply Market
MACRO GROWTH DRIVERS
Increasing Healthcare Expenditure Aids Pen Drives Market Growth
World Healthcare Expenditure (In US$ Trillion) for the Years for 2017, 2019, 2021, 2023
Increasing Obesity Levels Underpins Market Growth
Average Per Capita Annual Health Expenditure (In US$) due to Obesity
Obesity Prevalence Rate (%) in Select Countries for the Years 2019 and 2030P
Rising Demand for Biosimilar Drugs Propel the Market for Pen Needles
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Pen Needles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 2: World Historic Review for Pen Needles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 3: World 16-Year Perspective for Pen Needles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
TABLE 4: World Recent Past, Current & Future Analysis for Standard by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 5: World Historic Review for Standard by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 6: World 16-Year Perspective for Standard by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 7: World Recent Past, Current & Future Analysis for Safety by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 8: World Historic Review for Safety by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 9: World 16-Year Perspective for Safety by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 10: World Recent Past, Current & Future Analysis for Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 11: World Historic Review for Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 12: World 16-Year Perspective for Insulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 13: World Recent Past, Current & Future Analysis for Glucagon-Like Peptide-1 (GLP-1) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 14: World Historic Review for Glucagon-Like Peptide-1 (GLP-1) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 15: World 16-Year Perspective for Glucagon-Like Peptide-1 (GLP-1) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 16: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 17: World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 18: World 16-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 19: World Pen Needles Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
Market Facts & Figures
US Pen Needles Market Share (in %) by Company: 2022 & 2030
Standard (Type) Market Share Analysis (in %) of Leading Players in the US for 2022 & 2030
Safety (Type) Competitor Revenue Share (in %) in the US: 2022 & 2030
Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
Market Analytics
TABLE 20: USA Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 21: USA Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 22: USA 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
TABLE 23: USA Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 24: USA Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 25: USA 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
CANADA
TABLE 26: Canada Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 27: Canada Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 28: Canada 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
TABLE 29: Canada Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 30: Canada Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 31: Canada 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
JAPAN
Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 32: Japan Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 33: Japan Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 34: Japan 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
TABLE 35: Japan Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 36: Japan Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 37: Japan 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
CHINA
Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 38: China Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 39: China Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 40: China 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
TABLE 41: China Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 42: China Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 43: China 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
EUROPE
Market Facts & Figures
European Pen Needles Market: Competitor Market Share Scenario (in %) for 2022 & 2030
Standard (Type) Market Share (in %) by Company in Europe: 2022 & 2030
Safety (Type) Market Share (in %) of Major Players in Europe: 2022 & 2030
Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
Market Analytics
TABLE 44: Europe Recent Past, Current & Future Analysis for Pen Needles by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 45: Europe Historic Review for Pen Needles by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 46: Europe 16-Year Perspective for Pen Needles by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 47: Europe Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 48: Europe Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 49: Europe 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
TABLE 50: Europe Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 51: Europe Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 52: Europe 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
FRANCE
Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 53: France Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 54: France Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 55: France 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
TABLE 56: France Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 57: France Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 58: France 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
GERMANY
Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 59: Germany Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 60: Germany Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 61: Germany 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
TABLE 62: Germany Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 63: Germany Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 64: Germany 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
ITALY
TABLE 65: Italy Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 66: Italy Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 67: Italy 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
TABLE 68: Italy Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 69: Italy Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 70: Italy 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
UNITED KINGDOM
Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 71: UK Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 72: UK Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 73: UK 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
TABLE 74: UK Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 75: UK Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 76: UK 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
SPAIN
TABLE 77: Spain Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 78: Spain Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 79: Spain 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
TABLE 80: Spain Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 81: Spain Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 82: Spain 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
RUSSIA
TABLE 83: Russia Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 84: Russia Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 85: Russia 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
TABLE 86: Russia Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 87: Russia Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 88: Russia 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 90: Rest of Europe Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 91: Rest of Europe 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 93: Rest of Europe Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 94: Rest of Europe 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Pen Needles by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 96: Asia-Pacific Historic Review for Pen Needles by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 97: Asia-Pacific 16-Year Perspective for Pen Needles by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 99: Asia-Pacific Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 100: Asia-Pacific 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 102: Asia-Pacific Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 103: Asia-Pacific 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
AUSTRALIA
Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
TABLE 104: Australia Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 105: Australia Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 106: Australia 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
TABLE 107: Australia Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 108: Australia Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 109: Australia 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
INDIA
Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
TABLE 110: India Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 111: India Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 112: India 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
TABLE 113: India Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 114: India Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 115: India 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
SOUTH KOREA
TABLE 116: South Korea Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 117: South Korea Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 118: South Korea 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
TABLE 119: South Korea Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 120: South Korea Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 121: South Korea 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 123: Rest of Asia-Pacific Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 126: Rest of Asia-Pacific Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
LATIN AMERICA
Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
TABLE 128: Latin America Recent Past, Current & Future Analysis for Pen Needles by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 129: Latin America Historic Review for Pen Needles by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 130: Latin America 16-Year Perspective for Pen Needles by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
TABLE 131: Latin America Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 132: Latin America Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 133: Latin America 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
TABLE 134: Latin America Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 135: Latin America Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 136: Latin America 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
ARGENTINA
TABLE 137: Argentina Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 138: Argentina Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 139: Argentina 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
TABLE 140: Argentina Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 141: Argentina Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 142: Argentina 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
BRAZIL
TABLE 143: Brazil Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 144: Brazil Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 145: Brazil 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
TABLE 146: Brazil Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 147: Brazil Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 148: Brazil 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
MEXICO
TABLE 149: Mexico Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 150: Mexico Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 151: Mexico 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
TABLE 152: Mexico Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 153: Mexico Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 154: Mexico 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
REST OF LATIN AMERICA
TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 156: Rest of Latin America Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 157: Rest of Latin America 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 159: Rest of Latin America Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 160: Rest of Latin America 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
MIDDLE EAST
Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
TABLE 161: Middle East Recent Past, Current & Future Analysis for Pen Needles by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 162: Middle East Historic Review for Pen Needles by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 163: Middle East 16-Year Perspective for Pen Needles by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
TABLE 164: Middle East Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 165: Middle East Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 166: Middle East 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
TABLE 167: Middle East Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 168: Middle East Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 169: Middle East 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
IRAN
TABLE 170: Iran Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 171: Iran Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 172: Iran 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
TABLE 173: Iran Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 174: Iran Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 175: Iran 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
ISRAEL
TABLE 176: Israel Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 177: Israel Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 178: Israel 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
TABLE 179: Israel Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 180: Israel Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 181: Israel 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
SAUDI ARABIA
TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 183: Saudi Arabia Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 184: Saudi Arabia 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 186: Saudi Arabia Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 187: Saudi Arabia 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
UNITED ARAB EMIRATES
TABLE 188: UAE Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 189: UAE Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 190: UAE 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
TABLE 191: UAE Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 192: UAE Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 193: UAE 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
REST OF MIDDLE EAST
TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 195: Rest of Middle East Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 196: Rest of Middle East 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 198: Rest of Middle East Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 199: Rest of Middle East 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
AFRICA
Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
TABLE 200: Africa Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 201: Africa Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 202: Africa 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
TABLE 203: Africa Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 204: Africa Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 205: Africa 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings